Clinical characteristics and survival outcome of isolated serous tubal intraepithelial carcinoma.

This cohort study included 157 patients with isolated serous tubal intraepithelial carcinoma and compared with 330 patients with stage IA high-grade serous fallopian tubal carcinoma identified in the Commission-on-Cancer's National Cancer Database from 2011 to 2017. Patients with isolated serous tubal intraepithelial carcinoma were younger, more likely to be non-Hispanic White, and had more recent diagnosis than those with stage IA high-grade serous fallopian tubal carcinoma. With a median follow-up of 7.2 years, the 7-year overall survival rate of patients with isolated serous tubal intraepithelial carcinoma exceeded 90%, which was higher than stage IA high-grade serous fallopian tubal carcinoma (93.2% vs 87.6%, adjusted-hazard ratio 0.30, 95% confidence interval 0.14 to 0.65). The majority of patients with isolated serous tubal intraepithelial carcinoma did not undergo lymph node evaluation and did not receive chemotherapy (82.2%). The 7-year overall survival rate of these patients remained higher than 90% (92.6%). In conclusion, these data suggest that isolated serous tubal intraepithelial carcinoma and stage IA high-grade serous fallopian tubal carcinoma have distinct clinical characteristics and survival. Although limited in sample size, favorable long-term survival without lymph node evaluation and chemotherapy for patients with isolated serous tubal intraepithelial carcinoma found in this study requires further validation and evaluation.